Thursday, February 14, 2013
Cancer drug discovery does not suffer from a dearth of
targets-instead it is in need of a way to prioritize target selection. Now, a
team from The Institute of Cancer Research has
created a computational algorithm that hones in on targets with strong
biological validation that also are predicted to be druggable.1 The
approach may provide a basis for systematically picking cancer targets.
A key next step for expanding the utility of the algorithm
will be incorporating additional clinical data, said Workman. The next version,
which will be released this summer, will include all of the genomic and
expression data from the International Cancer Genome Consortium. This
additional clinical data will expand the algorithm to help compare the level of
biological validation of potential targets in addition to weighing likely
Kotz, J. SciBX 6(6); doi:10.1038/scibx.2013.128
Published online Feb. 14, 2013
1. Patel, M.N. et al.
Nat. Rev. Drug Discov.; published online Dec. 31, 2012; doi:10.1038/nrd3913
Contact: Bissan Al-Lazikani, The Institute of Cancer Research, London,
Contact: Paul Workman, same affiliation as above
2. James, L.I. et al.
Nat. Chem. Biol.; published online Jan. 6, 2013; doi:10.1038/nchembio.1157
AND INSTITUTIONS MENTIONED
Cancer Research UK, London, U.K.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
The Institute of Cancer Research, Sutton, U.K.
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J.
Sage Bionetworks, Seattle, Wash.
The University of North Carolina at Chapel Hill Eshelman
School of Pharmacy,
Chapel Hill, N.C.